Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07532473 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

REal World MAIA UK OutcomEs

Study acronym: REMAKE
StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jul 2026 to Dec 2026
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 3 of 7 entries
    • Collaborators: details revised at 1 of 1 entry
  2. Study description shortened, about 7 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.
Trial Details
NCT Number NCT07532473
Lead Sponsor The Royal Wolverhampton Hospitals NHS Trust
Collaborators: Johnson & Johnson
Conditions
(from sponsor)		 Myeloma
Related terms Neoplasms, Plasma Cell
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov